Le Lézard
Classified in: Health, Science and technology, Business
Subject: FNC

Neurelis Secures Senior Term Loan Facility Of Up To $150 Million From OrbiMed


SAN DIEGO, Aug. 11, 2021 /PRNewswire/ -- Neurelis, Inc., announced today that it has completed a senior term loan facility of up to $150 million from OrbiMed, one of the leading investors in the healthcare industry, to help fuel the company's future growth. 

Craig C. Chambliss, President and Chief Executive Officer of Neurelis, states, ""We are very pleased to partner with OrbiMed. This funding allows Neurelis to continue investing in the commercial growth of VALTOCO® (diazepam nasal spray) as well as developing our internal pipeline and potentially accessing external opportunities that may strengthen our position as an innovative neuroscience company."

The facility provides up to $150 million in financing. A first tranche facility of $65 million (Tranche A) is available at closing, with an additional $35 million (Tranche B) available at Neurelis' option by March 31, 2022, subject to certain conditions, and an additional tranche of up to $50 million (Tranche C) can be accessed by June 30, 2023, at OrbiMed's option, in support of potential future strategic opportunities such as licensing opportunities.

About OrbiMed

OrbiMed is a leading healthcare investment firm, with approximately $19 billion in assets under management. OrbiMed invests globally across the healthcare industry through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed's team of over 100 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya and other key global markets.

About Neurelis

Neurelis, Inc., is a commercial-stage neuroscience company focused on the development and commercialization of therapeutics for the treatment of epilepsy and orphan neurologic disorders characterized by high unmet medical need. In 2020, the FDA approved Neurelis's VALTOCO® (diazepam nasal spray) as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from an individual's usual seizure pattern in adult and pediatric patients 6 years of age and older. VALTOCO is a proprietary formulation of diazepam incorporating the science of INTRAVAIL®. Intravail's transmucosal absorption enhancement technology enables the noninvasive delivery of a broad range of protein, peptide and small-molecule drugs. In its approval of VALTOCO, the U.S. Food and Drug Administration also granted Neurelis Orphan Drug Exclusivity and recognized VALTOCO's intranasal route of administration as a clinically superior contribution to patient care over the previously approved standard-of-care treatment (a rectal gel formulation of diazepam). For more information on VALTOCO, please visit www.valtoco.com. In addition to VALTOCO, Neurelis is developing NRL-2 for intermittent use to control acute panic attacks, NRL-3 as a noninvasive acute therapy to stop seizures that have progressed to status epilepticus, and NRL-4 as a noninvasive rescue therapy to address the escalation of acute agitation symptoms associated with schizophrenia and bipolar 1 mania in adults. In addition, Neurelis is developing NRL-1049 (previously known as BA-1049), an investigational, pre-clinical stage small molecule Rho kinase (ROCK) inhibitor, for the treatment of cerebral cavernous malformations (CCMS), a rare disorder of the central nervous system (CNS). For more information on Neurelis, please visit www.neurelis.com.

Important Safety Information about VALTOCO:

Indication
VALTOCO® (diazepam nasal spray) is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 6 years of age and older.

IMPORTANT SAFETY INFORMATION

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS

Contraindications: VALTOCO is contraindicated in patients with:

Central Nervous System (CNS) Depression

Benzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating machinery, driving a motor vehicle, or riding a bicycle, until the effects of the drug, such as drowsiness, have subsided, and as their medical condition permits.

The potential for a synergistic CNS-depressant effect when VALTOCO is used with alcohol or other CNS depressants must be considered, and appropriate recommendations made to the patient and/or care partner.

Suicidal Behavior and Ideation

Antiepileptic drugs (AEDs), including VALTOCO, increase the risk of suicidal ideation and behavior. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or unusual changes in mood or behavior.

Glaucoma

Benzodiazepines, including VALTOCO, can increase intraocular pressure in patients with glaucoma. VALTOCO may only be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. VALTOCO is contraindicated in patients with narrow-angle glaucoma.

Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preservative

VALTOCO is not approved for use in neonates or infants. Serious and fatal adverse reactions, including "gasping syndrome", can occur in neonates and low-birth-weight infants treated with benzyl alcohol-preserved drugs, including VALTOCO. The "gasping syndrome" is characterized by central nervous system depression, metabolic acidosis, and gasping respirations. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known.

Adverse Reactions

The most common adverse reactions (at least 4%) were somnolence, headache, and nasal discomfort.

Diazepam, the active ingredient in VALTOCO, is a Schedule IV controlled substance.

To report SUSPECTED ADVERSE REACTIONS, contact Neurelis, Inc. at 1-866-696-3873 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Please read full Prescribing Information, including Boxed Warning, for additional important safety information.

For More Information:
Mark Leonard
mark@reachthenextlevel.com
858-251-2100

 

SOURCE Neurelis, Inc.


These press releases may also interest you

at 22:30
Bright Scholar Education Holdings Limited ("Bright Scholar" or the "Company") , a global premier education service company, today announced that it had filed its annual report on Form 20-F (the "Annual Report") for the fiscal year ended August 31,...

at 22:20
Easy Ice, a nationwide commercial ice machine lease and service provider, will hold a job fair January 20th from 4:30 p.m. to 7 p.m. at their branch in Lenexa, Kansas. Easy Ice seeks to fulfill numerous positions during the event. Open positions...

at 22:00
In the past two years, the development of the new energy automotive industry chain has been in full swing, which is predicated on the support of policies. For example, in the past few years, policies have rendered assistance to new energy automotive...

at 21:50
BIT Mining Limited ("BIT Mining" or the "Company"), a leading technology-driven cryptocurrency mining company, today announced its progress in the construction and buildout of its Ohio mining site in North America. In collaboration with its partner,...

at 20:10
Pomerantz LLP notifies investors of eHealth, Inc. ("eHealth" or the "Company") of a pending lawsuit against eHealth and certain of its officers. The class action, In re eHealth Inc. Securities Litigation, No. 4:20-cv-02395-JST (the "Class Action"),...

at 20:06
Covanta Holding Corporation (the "Company") announced today the early results of its previously announced cash tender offer (the "Offer") for any and all of its $400 million aggregate principal amount of outstanding 6.000% Senior Notes due 2027 (the...



News published on 11 august 2021 at 09:00 and distributed by: